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Abstract
Background: The inflammatory nature of atherosclerosis provides a broad range of potential molecular targets
for atherosclerosis imaging. Growing interest is focused on targets related to plaque vulnerability such as the
co-stimulatory molecules CD80 and CD86. We investigated in this preclinical proof-of-concept study the
applicability of the CD80/CD86-binding fusion protein belatacept as a probe for atherosclerosis imaging.
Methods: Belatacept was labeled with indium-111, and the binding affinity was determined with CD80/CD86-positive
Raji cells. In vivo distribution was investigated in Raji xenograft-bearing mice in single-photon emission computed
tomography (SPECT)/CT scans, biodistribution, and ex vivo autoradiography studies. Ex vivo SPECT/CT experiments
were performed with aortas and carotids of ApoE KO mice. Accumulation in human carotid atherosclerotic plaques
was investigated by in vitro autoradiography.
Results: 111In-DOTA-belatacept was obtained in >70 % yield, >99 % radiochemical purity, and ~40 GBq/μmol specific
activity. The labeled belatacept bound with high affinity to Raji cells. In vivo, 111In-DOTA-belatacept accumulated
specifically in Raji xenografts, lymph nodes, and salivary glands. Ex vivo SPECT experiments revealed displaceable
accumulation in atherosclerotic plaques of ApoE KO mice fed an atherosclerosis-promoting diet. In human plaques,
binding correlated with the infiltration by immune cells and the presence of a large lipid and necrotic core.
Conclusions: 111In-DOTA-belatacept accumulates in CD80/CD86-positive tissues in vivo and in vitro rendering it a
research tool for the assessment of inflammatory activity in atherosclerosis and possibly other diseases. The tracer is
suitable for preclinical imaging of co-stimulatory molecules of both human and murine origin. Radiolabeled belatacept
could serve as a benchmark for future CD80/CD86-specific imaging agents.
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Background
The innate and adaptive immune systems interact in
a well-orchestrated manner upon recognition of an
antigen. After antigen exposure, professional antigen-
presenting cells (APC), such as dendritic cells (DC),
lose phagocytic action simultaneously gaining antigen-
presenting capability by the upregulation of major
histocompatibility complex (MHC) receptors and the
co-stimulatory molecules CD80 (B7.1) and CD86 (B7.2)
[1]. The interactions of CD80 and CD86 with their T cell
receptor cytotoxic T lymphocyte protein 4 (CTLA-4,
CD152) and CD28 belong to the best-characterized co-
stimulatory pathways in immune response, determining
whether antigen exposure results in immune tolerance or
T cell activation [2]. The interactions between the co-
stimulatory molecules and their T cell receptors and
the resulting immune response are determining factors
for the course of various diseases including atheroscler-
osis, cancer, transplant rejection, and autoimmune
diseases [1, 3, 4].
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In atherosclerosis research, Buono et al. demonstrated
that LDL receptor (Ldlr) knockout (KO) mice lacking
CD80 and CD86 displayed a delayed atherosclerosis pro-
gression compared to control Ldlr KO mice [5]. The in-
volvement of CD80 and CD86 in vascular remodeling
was presented by Ewing et al. in a femoral artery cuff
mouse model [6]. We recently found significantly higher
relative messenger RNA (mRNA) levels of CD80 and
CD86 in human vulnerable than stable carotid plaques,
supported by immunohistochemistry data [7]. Our re-
sults were in agreement with a study on human carotid
and coronary plaques by Erbel et al. [8]. They observed a
higher CD86 mRNA expression in human carotid pla-
ques of symptomatic than asymptomatic patients. Their
immunohistochemical analysis revealed that virtually all
mature DCs were CD86-positive and in close proximity
to activated T cells. Further evidence for an involvement
of mature APCs in atherosclerosis was presented in an
expression analysis of human carotid endarterectomized
plaques [9]. CD11c, CD80, CD83, and CD86 mRNA ex-
pression was significantly higher in vulnerable than
stable plaques. The increase in vulnerable plaques was
more pronounced for the mature subpopulation of DCs
than the total number including immature DCs [9].
Altogether, these studies indicate that advanced ather-
oma contain a population of fully maturated DCs and
macrophages expressing co-stimulatory molecules and
that these APCs could be efficient regulators of T cell
activity in atherosclerosis. Antigen presentation is not
restricted to lymph nodes but additionally occurs in ath-
erosclerotic plaques as supported by co-localization data
of DCs and T cells [7, 8, 10].
Since activated APCs that express CD80 and CD86
are a primary component of atherosclerotic lesions
and the amount of APCs correlates with plaque vul-
nerability [9–11], CD80 and CD86 may be promising
imaging targets in atherosclerosis. We recently evalu-
ated CD80 as a target for non-invasive imaging by
positron emission tomography (PET) [7]. An oxodihy-
dropyrazolocinnoline derivative labeled with carbon-
11 showed high binding affinity to CD80 and bound
to CD80-positive Raji xenografts and in a displaceable
manner to endarterectomized human carotid plaques
both in vitro. However, the low tissue distribution of
the carbon-11-labeled ligand was a limiting factor in
pilot PET experiments with mice [7].
Abatacept (CTLA4-Ig, Orencia®, Bristol Myers Squibb)
and belatacept (LEA29Y, Nulojix®, Bristol Myers Squibb)
are 90-kDa fusion proteins of the extracellular domain
of human CTLA-4 and a modified Fc fragment of a hu-
man IgG1, used in the therapy against rheumatoid arth-
ritis and transplant rejection, respectively, inhibiting
CD80/CD86-mediated T cell activation. Belatacept dif-
fers by two amino acids from abatacept and the CTLA-4
extracellular domain, resulting in a 10-fold increased in-
hibition of T cell co-stimulation in vitro [12]. Surface
plasmon resonance measurements revealed high binding
affinities of belatacept to human and mouse CD80 as
well as CD86 [12, 13].
In the present proof-of-concept study, we evaluated
the potential of CD80/CD86-specific belatacept for ath-
erosclerosis imaging. We labeled belatacept with the
gamma-emitting nuclide indium-111 (physical half-life
2.8 days) and characterized its binding affinity to human
CD80/CD86 and its stability in plasma in vitro. The
111In-labeled probe was further evaluated by in vivo and
ex vivo single-photon emission computed tomography
(SPECT) with mice regarding its accumulation in CD80/
CD86-positive murine tissues and human CD80/CD86-
positive xenografts. Moreover, ex vivo SPECT scans were
acquired in a mouse model of atherosclerosis. Finally,
the in vitro binding of 111In-DOTA-belatacept to human
carotid plaques was compared with histological markers
of plaque inflammation.
Methods
Ethics, consent, and permissions
All procedures performed in studies involving human
participants were in accordance with the ethical stan-
dards of the institutional and national research commit-
tees and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards. Informed
consent was obtained from all individual patients in-
cluded in the study prior to surgery.
All applicable international, national, and institutional
guidelines for the care and use of animals were followed,
in particular the Swiss legislation and FELASA guide-
lines. All experiments with animals were approved by
the veterinary office of the Kanton Zurich.
Conjugation, radiolabeling, quality control, and stability
Commercially available belatacept (Nulojix®, Bristol Myers
Squibb) was conjugated to p-SCN-Bn-DOTA (S-2-(4-iso-
thiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraa-
cetic acid, B205, Macrocyclics, Dallas, TX) and labeled
with indium-111 according to a published procedure
[14]. The conjugation reaction is described in Additional
file 1. The conjugate was characterized by liquid
chromatography-mass spectrometry (LC-MS).
For radiolabeling, each 10 μg protein conjugate
was reacted with 4 MBq 111In (Mallinckrodt, Dublin,
Ireland) as optimized by incubation of a fixed amount of
belatacept-DOTA with increasing amounts of 111In. The
reaction mixture for the radiolabeling contained 300–
350 μg belatacept-DOTA (175 μL), 0.1 M ammonium
acetate buffer (pH 6, 60 μL), and 111In (111InCl3 in 0.02 N
HCl, 213–228 MBq, 215 μL, Mallinckrodt). After 1 h in-
cubation at room temperature (rt), the reaction was
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quenched by the addition of 50 mM EDTA solution
(10 %, v/v), mixed and allowed to incubate for 5 min at rt.
The product was purified, and its stability in phosphate-
buffered saline (PBS) and plasma was investigated as de-
scribed in Additional file 1.
In vitro experiments
Cell culture, immunocytochemistry, binding studies with
Raji and NCI-H69 cells and tissue staining are described
in detail in Additional file 1. In brief, Raji (human
Burkitt’s lymphoma cell line, ATCC CCL-86) and NCI-H69
cells (human lung small cell carcinoma cell line, ATCC
HTB-119) were purchased from the German Collection of
Microorganisms and Cell Cultures (DSMZ, Braunschweig,
Germany) and were cultured according to the supplier’s
protocols.
For immunocytochemistry, the following primary
antibodies were used: anti-CD80 1:100 (2A2, ab86473,
Abcam, Cambridge, UK), anti-CD86 1:200 (EP1158Y,
ab53004, Abcam, Cambridge, UK), and anti-CTLA-4
1:100 (MO6, clone 2F1, H00001493-M06, Abnova,
Taipei, Taiwan). Additionally, the following secondary
antibodies were used: goat anti-rabbit IgG H&L
1:1000 (FITC, ab6717, Abcam, Cambridge, UK) and
goat anti-mouse IgG H&L 1:1000 (FITC, ab6785, Abcam,
Cambridge, UK). Cells were fixed in paraformalde-
hyde and permeabilized with methanol. Nuclei were
stained with 4′,6-diamidino-2-phenylindole (DAPI).
Binding affinity was determined in saturation binding
and Lindmo assays with Raji and NCI-H69 cells as
described in Additional file 1.
In vivo and ex vivo studies with xenograft-bearing mice
Five-week-old female CD1 nu/nu mice (Crl: CD1-
Foxn1nu) from Charles River Laboratories (Sulzfeld,
Germany) were fed a normal chow diet ad libitum.
At the age of 6 weeks, these immune-deficient mice
were subcutaneously inoculated in their shoulder re-
gion with 1 × 107 Raji cells in 100 μL Matrigel (BD
Biosciences, Oxford, UK) (4 animals both sides, 6
animals right side). NCI-H69 cells (1 × 107 in 100 μL
Matrigel) were subcutaneously inoculated in the shoulder
region of CD1 nu/nu mice 2 weeks afterwards (2 animals
both sides, 6 animals with Raji xenografts, see above, op-
posite side). In vivo SPECT/CT scans, ex vivo autoradiog-
raphy, and biodistribution experiments were performed
2 weeks after the second inoculation according to
Additional file 1: Table S1. Animals were injected
intravenously with 10 MBq 111In-DOTA-belatacept
(25 μg, baseline) or 10 MBq 111In-DOTA-belatacept
and 500 μg unlabeled belatacept (blockade). In vivo
and ex vivo experiments were performed 48 h after
tracer injection or as indicated.
ApoE KO atherosclerosis mouse models and C57BL/6
control mice
Eleven-week-old male C57BL/6 mice (control) and four-
week-old male ApoE KO mice (B6.129P2-Apoetm1Unc/J)
were obtained from Charles River Laboratories. Two
C57BL/6 mice and two ApoE KO mice were fed a
normal chow diet ad libitum. All other ApoE KO mice
(n = 4) received a modified Western-type diet containing
21 % fat, 0.25 % cholesterol, and 19.5 % casein (Kliba
Nafag, Kaiseraugst, Switzerland) ad libitum. In two ApoE
KO animals, fed a modified Western-type diet for
4 weeks, flow-modifying implants (cuff ) were placed
around the right and left common carotid arteries ac-
cording to previous publications, inducing atheroscler-
otic plaque formation up- and downstream [15, 16]. A
detailed characterization of the mouse model under the
above conditions, including a histological assessment,
gene expression analysis, and oil red o staining, is shown
elsewhere (Meletta et al., manuscript submitted). Mice
were used for ex vivo SPECT/CT experiments 19 weeks
after surgery. 111In-DOTA-belatacept (10 MBq, 25 μg,
baseline) or 10 MBq 111In-DOTA-belatacept and 500 μg
unlabeled belatacept (blockade) was injected into the tail
vein of the animals. Mice were euthanized 48 h after
tracer injection for ex vivo SPECT/CT imaging and oil
red o staining of the excised aorta and carotids. The two
mice with implants were in addition scanned before
euthanasia.
SPECT/CT imaging
In vivo and ex vivo SPECT/CT scans were conducted
with a four-head multiplexing multipinhole camera
(NanoSPECT/CT, Bioscan, Washington, DC, USA). The
acquisition time per view depended on the amount of
radioactivity at scan start in the field of view, and the
resulting scan times ranged from 20 min to 1 h (in vivo
scans) and 14.5 to 15.5 h (ex vivo scans). In vivo scans
were performed 48 h after tracer injection or as indi-
cated. For ex vivo studies, animals were euthanized
∼48 h after tracer injection and SPECT/CT images were
acquired after sample preparation. For in vivo SPECT/
CT scans, animals were anesthetized with isoflurane
(1.5–4 %) in oxygen. SPECT data were reconstructed
with HiSPECT software (Scivis GmbH, Göttingen,
Germany), and images were generated with the Nucline
Software (Bioscan). The fused SPECT and CT data were
analyzed using VivoQuant image post-processing software
(inviCRO Imaging Services and Softwares, Boston, USA)
and PMOD biomedical image quantification software
(PMOD Technologies, Zurich, Switzerland). For the
ex vivo scans, volumes of interest (VOIs, ~1 cm3) were
drawn manually to include aorta and carotids. A VOI
of equal size was drawn outside the tissue samples to
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define background radioactivity in the absence of tissue.
Tissue-to-background and tissue baseline-to-blocked ra-
tios were calculated from the averaged 5 voxels with the
highest radioactivity per VOI.
Biodistribution experiments
Post-mortem biodistribution studies with inoculated
CD1 nu/nu mice (Raji xenograft right and NCI-H69
xenograft left shoulder) were performed with three base-
line animals and three blockade animals. Animals were
euthanized with CO2 followed by cervical dislocation.
Tissues, organs, and a defined volume of original injec-
tate were weighed and counted for radioactivity in a
gamma counter (Packard Cobra II Auto Gamma, Perki-
nElmer). Accumulated tissue radioactivity was expressed
as % injected dose (Bq) per g tissue (% ID/g).
Ex vivo autoradiography
For ex vivo autoradiographic studies, CD1 nu/nu mice
bearing either Raji or NCI-H69 xenografts on both
shoulders were injected with ~10 MBq tracer and eutha-
nized after 48 h as described above. Tumors were dis-
sected, embedded in Tissue-Tek O.C.T. medium, and
frozen at −80 °C, and sections of 5 μm were prepared
using a cryostat. After drying, frozen sections were ex-
posed to super-resolution imager plates (PerkinElmer,
Waltham, MA, USA) for 5 min and analyzed by a Cyc-
lone® Plus Storage Phosphor System (PerkinElmer).
Radioactivity signals were quantified with the software
OptiQuant (5.0, PerkinElmer).
Human atherosclerotic carotid plaques
Atherosclerotic carotid plaques were obtained from pa-
tients undergoing carotid endarterectomy (CEA) at the
University Hospital of Zurich, Switzerland. Indications
for CEA were stroke, transient ischemic attack, on-
pump surgery to prevent perioperative stroke, ultra-
sound diagnosis revealing a soft and unstable plaque, or
other surgical interventions (e.g. aortic valve, coronary
artery surgery). Twenty-three patients were included in
this study with an average age of 75.4 ± 6.8 years, 16
were of male gender, 4 females, and 3 were unknown.
Plaque material was collected from all patients from the
common, external, and internal carotid artery. Available
details of the patients and the samples used in this study
are shown in Additional file 1: Table S2. Plaque speci-
mens were stored in RNAlater® solution (Sigma-Aldrich,
St. Louis, USA) at −80 °C. After thawing, plaques were
embedded in Tissue-Tek O.C.T. medium and cryosec-
tions (20 μm) were prepared with a cryostat. Frozen
sections were stored at −20 °C until further use.
In vitro autoradiography
Radiotracer binding was evaluated by in vitro auto-
radiography with sections of human carotid plaques
(20 μm). Cryosections were thawed at rt for 30 min and
preincubated for 10 min on ice in HEPES buffer (50 mM
HEPES, 5 mM MgCl2, 125 mM NaCl, 1 mM CaCl2, pH
7.4) supplemented with 0.5 % milk powder and
40 μM gammanorm (Octapharma AG, Lachen,
Switzerland). Gammanorm contains human immuno-
globulins that block unspecific binding of belatacept
to ubiquitous Fc receptors. Tissues were incubated
with 17 nM 111In-DOTA-belatacept (specific activity
36.6 GBq/μM) diluted in the above-specified buffer
(~100 μL) for 1 h on ice. For blockade conditions, add-
itionally 10 μM unlabeled belatacept was added to the
tracer solution. The sections were washed with HEPES
buffer containing milk powder and gammanorm (5 min,
4 °C), 3× HEPES buffer (5 min, 4 °C), and finally 2×
distilled water (10 s, 4 °C) and were dried at rt. Standards
of 1 μL tracer solution dried on 0.87 cm2 filter papers
were prepared as positive controls. The sections and
the standards were exposed to a super-resolution
imager plate (PerkinElmer) for 30 min and 14 h. The
plate was scanned by a Cyclone® Plus Storage Phosphor
System (PerkinElmer), and data was analyzed with the
software OptiQuant (5.0, PerkinElmer). Specific bind-
ing was calculated from the difference between the in-
tegrated radioactivity signals per area (DLU/mm2)
under baseline and blocking conditions, divided by the
value under baseline conditions. Hematoxylin and eosin
(HE) staining was performed with all sections to inves-
tigate tissue morphology and score each individual
plaque specimen used in autoradiography according to
Additional file 1: Table S3. A direct comparison with
immunohistochemistry for CD80 and/or CD86 as per-
formed in our previous study [7] was not performed as
both 111In-DOTA-belatacept autoradiography with
paraffin-embedded tissues and immunohistochemistry
with cryosections were not successful. In addition, the
poor resolution of the 111In autoradiography did not
allow the microscopic localization of tracer accumula-
tion in the sections. In total, 37 carotid specimens
were used for autoradiography experiments. The dis-
tribution of the plaques per classification category and
the individual details on patients and tissues are shown in
Additional file 1: Tables S2 and S4.
Statistics
Statistical data analysis was performed with GraphPad
Prism (GraphPad, La Jolla, CA, USA) or Microsoft Excel.
To assess the intergroup difference of two groups, a
two-tailed unpaired Student’s t test was performed. For
more than two groups, data was analyzed with a one-
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way ANOVA with a Tukey’s multicomparison test. A
p value <0.05 was considered significant.
Results
Conjugation, radiolabeling, and quality control of
111In-DOTA-belatacept
The bifunctional chelating agent p-SCN-Bn-DOTA was
successfully conjugated to belatacept under aqueous con-
ditions by reaction with lysine amino groups of the protein
according to a published procedure [14]. A 20-fold excess
of chelating agent resulted in an average DOTA/protein
molar ratio of 1.9 as determined by LC-MS. The so pre-
pared protein conjugate was labeled with indium-111 and
purified by semi-preparative fast-protein liquid chroma-
tography (FPLC). After purification, 111In-DOTA-belata-
cept was obtained in a radiochemical yield of 73–78 %, a
radiochemical purity of >99 %, and a specific activity of
36–41 GBq/μmol (n = 3).
Stability of 111In-DOTA-belatacept
The stability of 111In-DOTA-belatacept at 37 °C in
PBS and human and murine plasma, respectively, was
investigated by FPLC up to 72 h (Additional file 1:
Figure S1). More than 75 % of radiolabeled product
was stable after 72 h incubation. After 48 h, corre-
sponding to the time of most in vivo experimentation,
96 % intact product was present in murine plasma. In
general, 111In-DOTA-belatacept displayed better stability
in plasma than in PBS.
Binding of 111In-DOTA-belatacept to CD80/CD86-positive
Raji cells
Immunocytochemistry experiments confirmed the pres-
ence of CD80, CD86, and CTLA-4 on the surface and/or
in the cytoplasm of Raji cells (Fig. 1a), in agreement with
previous studies [17, 18]. A dissociation constant (Kd) of
17.6 nM for 111In-DOTA-belatacept was determined in a
saturation binding assay with CD80/CD86-positive Raji
cells (Fig. 1b). The binding potential of 111In-DOTA-bela-
tacept to Raji and control NCI-H69 cells was in addition
evaluated in Lindmo assays. In Raji cells, the immunoreac-
tivity of 111In-DOTA-belatacept was 28.3 % and binding
was considered specific as incubation with 0.1 mM
unlabeled belatacept resulted in a reduced radiotracer
binding (Fig. 1c). Binding to NCI-H69 cells was below
5 % and non-specific (data not shown), in agreement
with the absence of CD80/CD86 [7].
Accumulation of 111In-DOTA-belatacept in
CD80/CD86-positive Raji xenografts in vivo
The in vivo distribution of 111In-DOTA-belatacept and its
accumulation in CD80/CD86-positive Raji and control
NCI-H69 xenografts was evaluated in CD1 nu/nu mice.
We have recently shown high expression of CD80 and
CD86 mRNA and protein in Raji xenografts and negligible
levels in NCI-H69 xenografts, both grown under identical
experimental conditions as in this study [7]. In addition,
immunofluorescence microscopy performed for CD86
confirmed its high level in Raji and low level or absence in
NCI-H69 xenografts (Additional file 1: Figure S2).
Fig. 1 a Representative immunofluorescence microscopy images of Raji cells stained with DAPI (blue) and anti-CD80, anti-CD86, or anti-CTLA-4 antibody
(green). The control samples were incubated with secondary antibody only. Scale bar 20 μm. b Saturation binding assay of 111In-DOTA-belatacept with
Raji cells. Specific binding was calculated by subtracting the non-specific binding (111In-DOTA-belatacept and excess unlabeled belatacept) from the total
binding (111In-DOTA-belatacept only). c Lindmo binding assay with a constant 111In-DOTA-belatacept concentration of 0.5 nM
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SPECT/CT scans were acquired 48 h (Fig. 2a, b), 18 h
(Fig. 2c), or 2 h (Additional file 1: Figure S2) after tracer
injection. Under baseline conditions, 111In-DOTA-bela-
tacept accumulated in the Raji xenografts, the axial and
inguinal lymph nodes, the salivary glands, and the liver
(Fig. 2a). The highest accumulation in Raji xenografts
was achieved in the scan 48 h after tracer injection. By
co-injection of the radiotracer and an excess of un-
labeled belatacept, radiotracer accumulation was re-
duced in the Raji xenografts, the lymph nodes, and the
salivary glands while the radioactivity was still high in
the liver (Fig. 2b). The mouse scanned 18 h post injec-
tion (p.i.) in Fig. 2c carried both a Raji and an NCI-H69
xenograft for direct comparison. As expected, tracer
Fig. 2 a–c In vivo SPECT/CT images acquired 48 h (a, b) or 18 h (c) after i.v. injection of ~10 MBq 111In-DOTA-belatacept (25 μg) in CD1 nu/nu
mice bearing Raji (R, encircled) and a NCI-H69 xenograft (N, encircled) on the shoulders, as indicated. b Blocking with 500 μg unlabeled belatacept.
L liver, LN lymph nodes, S salivary glands, U urinary bladder. Colors, SPECT signal (estimated % ID/g) according to scale bar; gray, computed
tomography (CT). d Representative ex vivo autoradiograms of Raji and NCI-H69 xenografts dissected 48 h p.i. of ~10 MBq 111In-DOTA-belatacept
(exposed on identical plate)
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uptake was higher in the Raji than the NCI-H69 xeno-
graft. Neither the Raji nor the NCI-H69 xenograft was
visible in the scan 2 h after injection while blood radio-
activity was still high as seen from the high signal in the
carotid arteries and the heart (Additional file 1: Figure
S2).
Ex vivo autoradiography analysis of CD80/CD86-posi-
tive Raji and control NCI-H69 xenografts were in agree-
ment with the SPECT/CT data. In autoradiograms, we
observed an overall higher radioactivity signal in Raji xe-
nografts under baseline than under blockade conditions
with a focal distribution pattern (Fig. 2d). The control
NCI-H69 xenograft displayed a low radiotracer accumu-
lation under baseline and blockade conditions indicating
a non-specific uptake of 111In-DOTA-belatacept that
was comparable to the signals observed in Raji xeno-
grafts under blockade conditions (Fig. 2d).
Quantitative radiotracer distribution in xenograft-
bearing CD1 nu/nu mice was evaluated in an ex vivo
biodistribution experiment with three animals each, 48 h
after injection of 111In-DOTA-belatacept (baseline) or
111In-DOTA-belatacept together with unlabeled belata-
cept (blockade). Under baseline conditions, the highest
percentage of injected dose per g tissue (% ID/g) was
found in the spleen, the axial and inguinal lymph nodes,
the liver, and the salivary glands, followed by the Raji
xenografts and the blood (Table 1). Radiotracer
accumulation was significantly higher in Raji than in
NCI-H69 xenografts. Under blockade conditions, a
significant reduction of radiotracer accumulation was ob-
served for the Raji xenografts (p = 0.0057, uncorrected 2-
tailed t test) and salivary glands (p = 0.0019).
Accumulation of 111In-DOTA-belatacept in murine
atherosclerotic plaques
ApoE KO mice on regular diet develop atherosclerotic
plaques in the aortic arch and the descending aorta. To
enhance and accelerate plaque formation, ApoE KO
mice were fed a high-fat diet. In two of these mice, pla-
ques were further provoked in the carotid arteries by
shear stress-modifying implants (cuffs; Meletta et al.,
manuscript submitted). Radiotracer accumulation in the
atherosclerotic plaques was evaluated by ex vivo SPECT/
CT imaging to allow an accurate localization of the
SPECT signal. Tissues were dissected 48 h after injection
of 111In-DOTA-belatacept.
In the implant-bearing animals, 111In-DOTA-belatacept
accumulated in defined regions of the carotids besides the
aortic arch and the descending aorta (Fig. 3a). The radio-
tracer signal co-localized with the lipid staining for athero-
sclerotic plaques; however, not all lipid-positive regions
were positive in SPECT scans. Radiotracer accumulation
was reduced under blockade conditions with an excess of
unlabeled belatacept (Fig. 3b). Plaque burden was
Table 1 Biodistribution data (% ID/g tissue) of baseline (n = 3) and blockade (n = 3) CD1 nu/nu mice with subcutaneous Raji and
NCI-H69 xenografts
n n
**p < 0.01, uncorrected 2-tailed t test
aComparing tissues under baseline conditions
bComparing a particular tissue under baseline and blocking conditions
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comparable in the baseline and the blockade tissues.
Quantification of the SPECT signal revealed a higher ra-
diotracer accumulation in the baseline than the blockade
aorta and carotids. Ratios of maximal radioactivity be-
tween plaques and background (outside tissue) were 3.5
and 2.3 under baseline and blocking conditions, respect-
ively, with a direct ratio of 1.5 between plaques baseline
and blocked signal. In vivo SPECT/CT images of these
mice, recorded before euthanasia, are provided in Add-
itional file 1: Figures S3 and S4. Tracer accumulation
was observed in the baseline animal upstream of the
right implant and where the aortic arch is expected;
however, high radioactivity in the adjacent tissues
challenged the interpretation of these images.
In the two ApoE KO animals without a cuff, fed a high-
fat diet, radiotracer accumulation was detected in the aor-
tic arch and the descending aorta (Fig. 3c). Vascular seg-
ments with high radiotracer binding were positive by lipid
staining, while additional large lipid-rich vascular areas
were not identified by SPECT. Under a standard rodent
diet, no 111In-DOTA-belatacept accumulation was ob-
served in ApoE KO (Fig. 3d) and C57BL/6 mice (Fig. 3e).
Oil red o staining revealed for the ApoE KO animals
under normal diet a small lipid accumulation limited to
the aortic arch, whereas in C57BL/6 animals, the lipid
staining was negative.
Accumulation of 111In-DOTA-belatacept in human carotid
plaques
After the encouraging results with the mouse models of
atherosclerosis, we investigated whether 111In-DOTA-
belatacept accumulates in human atherosclerotic plaques
and whether the accumulation correlates with characteris-
tics of plaque vulnerability. Radiotracer binding to human
carotid plaques was evaluated by in vitro autoradiography.
After the autoradiography experiments, plaques were clas-
sified by histological analysis according to the following
equally weighted criteria: (i) size of the lipid/necrotic core,
(ii) number of immune cells (foam cells and macrophages),
(iii) cap thickness, and (iv) cap rupture (Additional file 1:
Table S3). The scale of total scores ranged from 0 to 8. In
total, 37 plaque samples were included in this study with a
heterogeneous distribution on the scoring scale and the
majority of samples displaying a score of 0 to 2 (Additional
file 1: Tables S2 and S4).
Figure 4 shows the HE staining of four plaque speci-
mens classified with a score of 0, 2, 4, and 7, respect-
ively. The sample with a score of 0 displayed an intact
and structured endothelium with no enclosed lipids or
immune cells (Fig. 4, I). A small focal accumulation of
lipids and immune cells was observed in the sample
classified with a score of 2 (Fig. 4, II, III). The sample
classified with a score of 4 featured a large lipid and nec-
rotic core covered by a thick fibrous cap (Fig. 4, IV, V).
The plaque was focally infiltrated by numerous macro-
phages and clusters of foam cells (Fig. 4, VI). The sample
with the highest score consisted of a large lipid and
necrotic core and displayed a heterogeneous plaque
composition (Fig. 4, VII) and the presence of many im-
mune cells (Fig. 4, IX). The representative and the
minimum cap thickness were <500 and <200 μm, re-
spectively (Fig. 4, VII, VIII).
Fig. 3 Ex vivo SPECT/CT images (upper row) and the corresponding oil red o staining (bottom row) of the aorta and carotids of
ApoE KO-cuff mice fed a high-fat diet (a, b), ApoE KO animals fed a high-fat diet (c), ApoE KO animals fed a normal diet (d), and
C57BL/6 mice fed a normal diet (e). Animals were injected intravenously with ~10 MBq 111In-DOTA-belatacept and sacrificed 48 h
p.i. b Blockade with co-injection of an excess of unlabeled belatacept. Color scales for relative % ID/g. Scale bars 1 mm. ApoE
KO-cuff mice (a, b) had flow-altering devices implanted around their carotids visible as transparent or reddish material fixed with a
black suture (asterisks). a and b were directly compared in one scan, c, d, and e in a second scan (color scales may differ between
the two panels)
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In the in vitro autoradiography experiment, 111In-
DOTA-belatacept bound to human carotid plaques and
the radiotracer binding was reduced under blockade
conditions with excess of unlabeled belatacept (Fig. 5a,
corresponding plaque samples to Fig. 4). Average radio-
tracer specific binding to samples with a score ≥2 was
higher than to samples with a score of 0–1, though not
with statistical significance (Fig. 5b). However, the spe-
cific binding of 111In-DOTA-belatacept correlated sig-
nificantly with the score for immune cell infiltration.
Moreover, a significantly higher specific radiotracer binding
was observed to plaques featuring a large lipid and necrotic
core than to plaques with a small core (Fig. 5d). Radioactiv-
ity accumulation and cap thickness did not correlate, and
the correlation between relative specific radioactivity and
total score was weak with a Pearson’s r2 of 0.275 (details of
the individual samples are shown in Additional file 1: Table
S2). In these experiments, unspecific binding to Fc recep-
tors was blocked by addition of human gamma globulin
to the autoradiography buffer. The respective signal
reduction was 10.9 ± 2.6 % (n = 3).
Discussion
In this proof-of-concept study, we successfully estab-
lished a radiolabeling procedure for the CD80/CD86-tar-
geting fusion protein belatacept with indium-111 using
p-SCN-Bn-DOTA as bifunctional chelating agent. After
purification, the product was obtained in high radio-
chemical yield and purity in a fast and robust labeling
reaction. Under the applied conditions, approximately
two DOTA chelators were coupled to belatacept which
is the intended range to minimize undesired chelator-
mediated effects on pharmacokinetics [19]. A high sta-
bility of the radiolabeled product was determined in PBS
and plasma of murine and human origin, respectively,
up to 72 h allowing in vivo investigations.
Fig. 5 a In vitro autoradiograms of human carotid plaques with
different scores under baseline (111In-DOTA-belatacept) and blockade
condition (111In-DOTA-belatacept with excess unlabeled belatacept).
Scale bar 3 mm. b–d Relative specific binding of 111In-DOTA-belatacept
determined by in vitro autoradiography. Samples were classified
according to their score (0–1: n = 11; ≥2: n = 21); no (n = 11), few
(n = 18, <50 cells), or many (n = 8, ≥50 cells) immune cells
(macrophages and foam cells); no (n = 11), small (n = 17, <50 % plaque
thickness, <25 % total cross-sectional area), or large (n = 9, ≥50 %
plaque thickness, ≥25 % total cross-sectional area) lipid/necrotic
core. ns non-significant, *p < 0.05
Fig. 4 Hematoxylin/eosin staining of the plaque sections corresponding to the autoradiograms in Fig. 5. Higher-magnification images show the
intact endothelium (I), endothelial thickening (II, III), a homogenous and thick fibrous cap (IV, V), foam cells (VI), a heterogeneous fibrous cap (VII),
a thin fibrous cap (VIII), and immune cells (IX). Scale bar lower magnification 2 mm, higher magnification 200 μm, and VI/IX 50 μm. Lu lumen
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The radiolabeled product bound to human Raji cells
with a nanomolar Kd value. Efforts to assess the binding
affinity to mouse recombinant CD80 by differential
scanning fluorimetry were not successful due to similar
melting temperatures Tm of the recombinant CD80
and belatacept. Immune-reactive affinity assays were
excluded due to interferences with the Fc portion of
belatacept. However, the results of this study indicate
that the radiolabeling modifications did not hamper
high-affinity binding to human and murine CD80/CD86
in vitro and in vivo. The contribution of Fc receptor-
mediated binding to the total binding of belatacept was
negligible as concluded from in vitro autoradiography
with human tissue and as expected from published
data [13].
In vivo SPECT/CT scans and ex vivo autoradiography
experiments indicated that 111In-DOTA-belatacept spe-
cifically accumulated in CD80/CD86-positive tissues.
Besides Raji xenografts, strong and specific accumula-
tion was observed in the lymph nodes. The lymph
nodes exhibit a resident population of APCs capable of
expressing CD80 and CD86 in particular during the
process of antigen presentation. Moreover, biodistribution
studies revealed the highest radiotracer accumulation in
the spleen, a peripheral lymphoid organ, and a high
specific accumulation in the salivary glands of xenograft-
bearing mice. This is consistent with the fact that APCs
are constituents of human and murine salivary glands be-
ing involved in immune surveillance [20, 21]. The high
non-specific hepatic radiotracer accumulation may be
related to the IgG1 Fc part of the fusion protein [22].
The accumulation of radioactivity in the Raji xeno-
grafts increased from 2 to 18 to 48 h p.i. This is in
agreement with the relatively long half-life in the blood
of IgG1 Fc fusion proteins. The half-life of the closely re-
lated abatacept in mice was ~90 h after i.v. injection
[23]. Indium-111 is thus a good choice for the labeling.
Its long physical half-life of 67 h allows scans up to sev-
eral days after tracer injection when a significant portion
of 111In-DOTA-belatacept is cleared from the blood.
The high and specific accumulation of 111In-DOTA-
belatacept in the lymph nodes of the xenograft-bearing
animals seen in SPECT and confirmed in the biodistribu-
tion experiments looks promising towards the imaging of
small CD80/CD86-rich structures. We, therefore, pro-
ceeded to an animal model of atherosclerosis where lesions
are of similar or smaller dimension. However, owing to the
proximity of atherosclerosis-prone areas in the aorta and
the carotids to other tissues with radiotracer accumulation,
e.g. the liver, the salivary glands, and the thymus, SPECT/
CT scans of aorta and carotids were performed ex vivo.
Furthermore, perfusion of the excised tissue allowed to ex-
clude any blood-related tracer radioactivity, considering the
long residence time of 111In-DOTA-belatacept in the blood
(still 7.6 % ID/g blood 48 h after injection). 111In-DOTA-
belatacept accumulated in lipid-rich atherosclerotic pla-
ques, and tracer accumulation was higher under baseline
than blockade condition. Moreover, 111In-DOTA-belatacept
accumulation in the aortas of ApoE KO animals was
dependent on an atherosclerosis-promoting diet. However,
several lipid-rich regions were not positive in SPECT.
We can only speculate on the reasons. SPECT imaging
with 111In-DOTA-belatacept may not have been sensi-
tive enough to visualize all lesions, depending on their
size and tracer uptake. The signal was close to the de-
tection limit in the ex vivo scans. Alternatively and in
addition, not all lipid-rich regions may be invaded by
high numbers of CD80/CD86-positive cells. As dis-
cussed under limitations, we did not further investigate
these vessel walls by immunohistochemistry. However,
we found that the descending aortas of ApoE KO mice
fed a high-fat diet contained significantly higher mRNA
levels of CD80 than the descending aortas of wild type
mice under normal diet (Meletta et al., manuscript sub-
mitted). In agreement with our findings, the correlation
between characteristics of plaque vulnerability and the
lipid content of the lesions may be weak as derived
from intravascular ultrasound measurements [24].
In human carotid tissue samples, 111In-DOTA-belatacept
binding was associated with the infiltration of immune
cells. It can be assumed that the majority of inflammatory
cells within a plaque are APCs [25]. The increasing number
of macrophages and mature DCs in advanced atheroscler-
otic lesions might promote the formation of a necrotic core
due to a loss of efferocytosis activity, an intensification of
the inflammatory response, and degradation of matrix com-
ponents [1, 26, 27]. This is in agreement with the observed
increase in 111In-DOTA-belatacept uptake in lesions
with a large lipid/necrotic core. Our results suggest that
111In-DOTA-belatacept accumulates specifically in athero-
sclerotic plaques, depending on their degree of inflamma-
tion and vulnerability.
Limiting factors are related to the small size of athero-
sclerotic plaques both in preclinical models and in humans.
High specific accumulation of radioactivity and low spill-
over from other tissues are required for the detection of le-
sions in the millimeter or submillimeter range [28]. The
long biological half-life of 111In-DOTA-belatacept is un-
favorable in this respect, as it contributes to significant un-
specific tissue radioactivity as observed in the in vivo scans.
Imaging vulnerable plaques in coronary arteries would be
even more challenging. According to the biodistribution
results, radioactivity in myocardium was still relatively high
48 h p.i., although unspecific and lower than in the blood.
This relatively high background level in the heart together
with the respiratory and myocardium motion would ham-
per detection of atherosclerotic lesions in coronary arteries
under these experimental conditions. A tracer with a faster
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clearance from the blood and CD80/CD86-negative tissues
in combination with motion correction from simultan-
eously acquired magnetic resonance imaging (MRI) may
improve the contrast between atherosclerotic lesions and
myocardium in the future.
Further limitations of our study are the low number of
animals used for in vivo and ex vivo imaging and the lack
of control animals to study lymph node accumulation of
111In-DOTA-belatacept in the absence of xenografts or
atherosclerosis. In addition, belatacept binds with similar
affinity to CD80 and CD86, which may reduce selectivity
for a particular type of cell activation as compared to a
CD80- or CD86-selective tracer. Due to technical limita-
tions with available antibodies, we were not able to coun-
terstain the atherosclerotic tissues from SPECT and
autoradiography for CD80 and CD86, the proteins that we
found upregulated in human vulnerable atherosclerotic
plaques [7]. Finally, a fusion protein would not fulfill all
requirements for clinical application as a PET imaging
agent primary due to its prolonged biological half-life of
8–9 days in humans in the case of belatacept and con-
cerns with respect to immunogenicity of proteins [29].
Future studies have to focus on CD80- or CD86-
selective small molecules and truncated versions of bela-
tacept as well as abatacept, which has a higher affinity
and selectivity for CD80 than CD86 in mouse [13]. In
this respect, 111In-DOTA-belatacept could serve as a
benchmarking tracer in the preclinical development of
novel CD80/CD86 imaging agents.
Conclusions
CD80 and CD86 expressed by activated APCs are
promising imaging targets in atherosclerosis. In this
context, 111In-DOTA-belatacept could serve as a re-
search tool to study the approach of targeting CD80/
CD86-rich APCs in atherosclerosis and possibly other
inflammation-related diseases such as cancer, auto-
immune disease, and rejection after organ transplant-
ation. A highly expedient characteristic of belatacept is
its immunoreactivity with both murine and human
CD80/CD86 allowing the translation between species.
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